Welcome to our dedicated page for BioSig Technologies news (Ticker: BSGM), a resource for investors and traders seeking the latest updates and insights on BioSig Technologies stock.
The BSGM news archive on Stock Titan covers the corporate evolution of BioSig Technologies, Inc. into Streamex Corp., a Nasdaq-listed company now trading under the symbol STEX. Company press releases and SEC-referenced announcements document the merger between BioSig Technologies and Streamex Exchange Corporation, the subsequent name change to Streamex Corp., and the ticker change from BSGM to STEX on the Nasdaq Capital Market.
Earlier news items in this history describe BioSig’s activities as a medical device technology company focused on the PURE EP™ Platform for electrophysiology procedures. More recent releases highlight the company’s strategic pivot toward real-world asset tokenization and gold-focused financial infrastructure through Streamex. Disclosures discuss Streamex as a gold tokenization and gold treasury business building institutional-grade infrastructure to bring the gold and commodities markets on chain.
Readers can find coverage of key developments such as the closing of the merger with Streamex Exchange Corporation, public offerings of common stock to purchase gold bullion under an investment policy, and a tokenized yield partnership agreement related to precious-metal lease and bond programs. News items also address plans to operate as a regulated participant in tokenized real-world asset markets, including engaging a specialist firm to manage the acquisition of a FINRA and SEC-registered broker-dealer.
For anyone tracking the company’s journey from its BSGM days to its current STEX identity, this news page provides a chronological view of material announcements, strategic partnerships, capital markets activity, and governance changes that define the transition from a medical device issuer to a gold tokenization and RWA-focused enterprise.
BioSig Technologies, Inc. (Nasdaq: BSGM) announced a registered direct offering of 2,187,500 shares of its common stock at $8.00 per share, totaling expected gross proceeds of $17.5 million. The company plans to use the net proceeds for commercialization, working capital, and general corporate purposes. The closing of this offering is anticipated around June 26, 2020, contingent on customary conditions. The offering is conducted under a previously filed shelf registration statement with the SEC.
BioSig Technologies (Nasdaq: BSGM) announced a collaboration with Catalent to develop a treatment for COVID-19 using its antiviral agent, merimepodib. Catalent will create two oral dosage forms of merimepodib, which has shown in vitro effectiveness against SARS-CoV-2. The partnership emphasizes US-based manufacturing and aims to expedite clinical trials. Catalent's St. Petersburg facility will handle production, leveraging its expertise in lipid-based formulations. This initiative aligns with urgent global needs for COVID-19 treatments, enhancing BioSig's potential market positioning.
BioSig Technologies (Nasdaq: BSGM) announced the commencement of patient enrollment in its Phase II trial for merimepodib, an oral antiviral treatment for COVID-19. The trial includes sites from the Mayo Clinic and Atlantic Health System. Merimepodib has shown effectiveness in reducing SARS-CoV-2 replication in preclinical studies. Previously developed for hepatitis C, it has undergone 12 clinical trials with over 400 patients. The company cites potential risks in its forward-looking statements regarding operations, competition, and regulatory approvals.
BioSig Technologies, Inc. (Nasdaq: BSGM) announced the initiation of Phase II clinical trials for its antiviral candidate, merimepodib, aimed at treating COVID-19 in hospitalized adults. These trials will partner merimepodib with remdesivir and involve multiple sites across the U.S., with results expected in Q3 2020. A conference call is scheduled for June 9, 2020, to discuss these developments. The company previously secured FDA clearance for the IND of merimepodib and has expanded patient enrollment sites, including St. David’s South Austin Medical Center.
BioSig Technologies, Inc. (Nasdaq: BSGM) has expanded its patient enrollment for its Phase II trial of merimepodib, an oral antiviral candidate for COVID-19, to St. David’s South Austin Medical Center. This facility is part of one of Texas's largest healthcare systems. The trial aims to include a diverse patient population, potentially accelerating results. Preclinical studies indicate that merimepodib effectively reduces SARS-CoV-2 replication. The trial's lead investigator is Dr. Brian Metzger, supported by a skilled clinical team from St. David's.
BioSig Technologies, Inc. (NASDAQ: BSGM) announced that two scientific sessions featuring its PURE EP(tm) System have been accepted for presentation at the Heart Rhythm Society 2020 Science. The sessions, titled ‘Cardiac Signal Acquisition and Clinical Considerations for Accurate Interpretation’, will take place on June 12 and July 1, 2020. Presented by esteemed electrophysiologists from Mayo Clinic, these sessions will address issues in cardiac signal acquisition and the implications of filter application in EP labs. This initiative reflects BioSig's commitment to advancing clinical data and technology in electrophysiology.
BioSig Technologies, Inc. (NASDAQ: BSGM) announced the issuance of U.S. Patent No. 10,645,017 for its PURE EP™ System, enhancing the protection of its technology aimed at improving electrocardiogram (ECG) fidelity during cardiac procedures. The patent addresses foundational systems for accurately recording low-amplitude signals during ablation. Additionally, BioSig's subsidiary, ViralClear Pharmaceuticals, filed five new provisional patent applications for its anti-viral treatment for COVID-19 using merimepodib, which shows efficacy in lab tests. These developments strengthen BioSig's innovation and market potential.
BioSig Technologies (Nasdaq: BSGM) announces plans to initiate a Phase II clinical trial for merimepodib, targeting adult hospitalized COVID-19 patients. This trial will assess the effectiveness of merimepodib in combination with remdesivir across multiple sites, with anticipated data release in Q3 2020. A recent article published by F1000 Research highlights the combination's success in reducing SARS-CoV-2 replication to undetectable levels in pre-clinical testing. The trial is led by Dr. Andrew D. Badley at the Mayo Clinic.
BioSig Technologies, Inc. has appointed Mr. Michael R. Dougherty to the Board of its subsidiary, ViralClear Pharmaceuticals. With over 30 years in the pharmaceutical industry, Dougherty has held significant roles at Celator Pharmaceuticals and Kalidex Pharmaceuticals. His expertise is expected to benefit ViralClear during an essential phase of clinical planning. Notably, ViralClear’s candidate, merimepodib, has shown promising results against RNA viruses, including COVID-19, with in-vitro studies indicating a 98% reduction in viral production.
BioSig Technologies announced the successful closing of a $10.8 million financing for its subsidiary, ViralClear Pharmaceuticals, at a pre-money valuation of $100 million. The funds will support Phase II clinical trials for merimepodib, an oral antiviral treatment targeting COVID-19, beginning at Mayo Clinic sites. The FDA recently cleared the IND application for the trials, highlighting investor confidence in BioSig's clinical program amid the ongoing pandemic.